Rapid correction of glucose may reduce blood flow to the optic nerve, depriving it of oxygen
Solving these hurdles requires a one health global partnership involving the medical, industry, academic, government, agricultural and healthcare sectors
Eli Lillys retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon receptors, remains in Phase 3 TRIUMPH trials as of mid-2026, with NDA submission projected no earlier than Q4 2026
The peptide has shown an excellent safety profile with minimal reported side effects, partly because it is a naturally occurring fragment of a human peptide
Example: A patient on tirzepatide 10mg weekly should start semaglutide 0.25mg once weekly for four weeks, then increase to 0.5mg and higher as tolerated
doi: 10.1001/jama.2017.7596